US drugmakers Merck and Moderna announced Wednesday positive results from the final-phase clinical trial of their experimental mRNA-based vaccine for treating skin cancer, aimed at patients with advanced-stage melanoma. According to AFP, the two companies said in a joint statement that this marks the first time positive Phase 3 trial results have been revealed for an mRNA-based cancer treatment. The personalized, patient-specific treatment, when used alongside Merck's immunotherapy drug Keytruda, produced a 'statistically significant' improvement in recurrence-free survival for advanced melanoma patients who had already undergone surgery, compared with Keytruda alone. The new treatment, called intismeran autogene, relies on mRNA technology that instructs the body's cells to produce proteins capable of triggering an immune response. It's a personalized treatment developed based on the specific mutations found in each patient's tumor, aiming to train and activate the patient's immune system to recognize and attack cancer cells.
US drugmakers Merck and Moderna announced Wednesday positive results from the final-phase clinical trial of their experimental mRNA-based vaccine for treating skin cancer, aimed at patients with advanced-stage melanoma. According to AFP, the two companies said in a joint statement that this marks the first time positive Phase 3 trial results have been revealed for an mRNA-based cancer treatment. The personalized, patient-specific treatment, when used alongside Merck's immunotherapy drug Keytruda, produced a 'statistically significant' improvement in recurrence-free survival for advanced melanoma patients who had already undergone surgery, compared with Keytruda alone. The new treatment, called intismeran autogene, relies on mRNA technology that instructs the body's cells to produce proteins capable of triggering an immune response. It's a personalized treatment developed based on the specific mutations found in each patient's tumor, aiming to train and activate the patient's immune system to recognize and attack cancer cells.
US drugmakers Merck and Moderna announced Wednesday positive results from the final-phase clinical trial of their experimental mRNA-based vaccine for treating skin cancer, aimed at patients with advanced-stage melanoma. According to AFP, the two companies said in a joint statement that this marks the first time positive Phase 3 trial results have been revealed for an mRNA-based cancer treatment. The personalized, patient-specific treatment, when used alongside Merck's immunotherapy drug Keytruda, produced a 'statistically significant' improvement in recurrence-free survival for advanced melanoma patients who had already undergone surgery, compared with Keytruda alone. The new treatment, called intismeran autogene, relies on mRNA technology that instructs the body's cells to produce proteins capable of triggering an immune response. It's a personalized treatment developed based on the specific mutations found in each patient's tumor, aiming to train and activate the patient's immune system to recognize and attack cancer cells.
comments
New mRNA Vaccine Shows Promise Against Skin Cancer
display options :
Full
Main image only
without images
comments